C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Watertown, MA.
相关临床试验
6
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
16.7%
已完成
1
16.7%
招募中
3
50.0%
终止
1
16.7%
暂无批准数据
- C4 Therapeutics has entered a new collaboration agreement with Roche to develop degrader-antibody conjugates (DACs), combining targeted protein degradation with antibody-drug conjugation technology. - The partnership focuses on two undisclosed oncology targets, with C4T receiving $20 million upfront and eligibility for over $1 billion in milestone payments plus tiered royalties. - DACs represent an emerging cancer therapy modality that leverages degrader payloads' catalytic mechanism to potentially overcome limitations of traditional ADCs. - This marks the third collaboration between the companies, building on a decade-long partnership that began in 2016 with Roche's early investment in targeted protein degradation.
- C4 Therapeutics plans to initiate the Phase 2 MOMENTUM trial of cemsidomide in Q1 2026, targeting fourth-line or later relapsed/refractory multiple myeloma patients with a recommended dose of 100 µg. - Phase 1 data demonstrated compelling anti-myeloma activity with 53% overall response rate at the 100 µg dose level in heavily pretreated patients, supporting cemsidomide's potential best-in-class profile. - The company has developed a regulatory pathway for two potential accelerated approvals and plans to submit a new drug application by year-end 2028. - C4 Therapeutics has secured cash runway through end of 2028 and is expanding its discovery strategy to target inflammation and neurodegenerative diseases.
- GT Biopharma successfully completed safety review for Cohort 3 of its Phase 1 GTB-3650 trial, with no safety or tolerability issues observed across six patients. - The company has advanced to Cohort 4 dosing at 10μg/kg/day, which represents a potential clinical efficacy threshold based on positive immunological biomarker trends. - GTB-3650 targets relapsed or refractory blood cancers expressing CD33 protein, including acute myeloid leukemia and high-risk myelodysplastic syndrome. - The hematologic malignancies treatment market reached $72 billion in 2025 and is projected to nearly double to $139 billion by 2034.
- The FDA has accepted Biogen's IND application for BIIB142, an IRAK4 protein degrader developed through collaboration with C4 Therapeutics, marking the first IRAK4 degrader to advance toward clinical trials for autoimmune diseases. - BIIB142 represents a breakthrough in targeted protein degradation technology, designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins in patients with autoimmune conditions. - Under the 2018 strategic collaboration, C4 Therapeutics delivered two development candidates to Biogen and will receive a $2 million milestone payment when patient dosing begins in the BIIB142 clinical trial. - The partnership combines C4T's expertise in targeted protein degradation with Biogen's drug development capabilities, addressing high unmet medical needs in autoimmune disease treatment.
- C4 Therapeutics is set to advance clinical development of cemsidomide, with Phase 1 data expected in late 2025 for multiple myeloma and non-Hodgkin’s lymphoma. - CFT1946, targeting BRAF V600 mutations in solid tumors, is progressing through Phase 1, with data readouts anticipated in the second half of 2025. - Phase 1 data from CFT8919, aimed at EGFR L858R-mutated non-small cell lung cancer, will inform future development plans outside of China. - C4 Therapeutics' cash runway is projected to fund operations into 2027, supporting ongoing research and clinical programs.
• Early-phase oncology trials are evolving to incorporate efficacy endpoints alongside safety, driven by novel targeted and immunotherapeutic agents. • Refining trial designs and patient selection is crucial to improve efficiency and maximize therapeutic intent in immunotherapeutic drug development. • Management of treatment-related adverse events from next-generation immunotherapies requires adaptive trial designs and specialized expertise. • Research aims to identify prognostic markers and implement pharmacodynamic markers to better assess novel immunotherapeutic agents.
- C4 Therapeutics presented Phase 1 data for CFT1946, a BRAF V600 degrader, at ESMO 2024, showing a well-tolerated safety profile in patients with advanced solid tumors. - Early data suggests CFT1946 demonstrates dose-dependent bioavailability and successfully degrades BRAF V600E protein, indicating proof of mechanism. - Initial anti-tumor activity was observed, with some patients achieving partial responses and tumor reductions across various BRAF V600 mutation types. - The Phase 1 trial continues with expansion cohorts exploring monotherapy and combination approaches, with additional data expected in 2025.
